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Glial glutamate transporter EAAT2 plays a major role in glutamate clearance in synaptic
clefts. Several lines of evidence indicate that strategies designed to increase EAAT2
expression have potential for preventing excitotoxicity, which contributes to neuronal injury
and death in neurodegenerative diseases. We previously discovered several classes of
compounds that can increase EAAT2 expression through translational activation. Here, we
present efficacy studies of the compound LDN/OSU-0212320, which is a pyridazine
derivative from one of our lead series. In a murine model, LDN/OSU-0212320 had good
potency, adequate pharmacokinetic properties, no observed toxicity at the doses examined,
and low side effect/toxicity potential. Additionally, LDN/OSU-0212320 protected cultured
neurons from glutamate-mediated excitotoxic injury and death via EAAT2 activation.
Importantly, LDN/OSU-0212320 markedly delayed motor function decline and extended
lifespan in an animal model of amyotrophic lateral sclerosis (ALS). We also found that
LDN/OSU-0212320 substantially reduced mortality, neuronal death, and spontaneous
recurrent seizures in a pilocarpine-induced temporal lobe epilepsy model. Moreover, our
study demonstrated that LDN/OSU-0212320 treatment results in activation of PKC and
subsequent Y-box–binding protein 1 (YB-1) activation, which regulates activation of EAAT2
translation. Our data indicate that the use of small molecules to enhance EAAT2 translation
may be a therapeutic strategy for the treatment of neurodegenerative diseases.
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Glial glutamate transporter EAAT2 plays a major role in glutamate clearance in synaptic clefts. Several lines of 
evidence indicate that strategies designed to increase EAAT2 expression have potential for preventing excito-
toxicity, which contributes to neuronal injury and death in neurodegenerative diseases. We previously dis-
covered several classes of compounds that can increase EAAT2 expression through translational activation. 
Here, we present efficacy studies of the compound LDN/OSU-0212320, which is a pyridazine derivative from 
one of our lead series. In a murine model, LDN/OSU-0212320 had good potency, adequate pharmacokinetic 
properties, no observed toxicity at the doses examined, and low side effect/toxicity potential. Additionally, 
LDN/OSU-0212320 protected cultured neurons from glutamate-mediated excitotoxic injury and death via 
EAAT2 activation. Importantly, LDN/OSU-0212320 markedly delayed motor function decline and extended 
lifespan in an animal model of amyotrophic lateral sclerosis (ALS). We also found that LDN/OSU-0212320 
substantially reduced mortality, neuronal death, and spontaneous recurrent seizures in a pilocarpine-induced 
temporal lobe epilepsy model. Moreover, our study demonstrated that LDN/OSU-0212320 treatment results 
in activation of PKC and subsequent Y-box–binding protein 1 (YB-1) activation, which regulates activation of 
EAAT2 translation. Our data indicate that the use of small molecules to enhance EAAT2 translation may be a 
therapeutic strategy for the treatment of neurodegenerative diseases.
Introduction
Glutamate is the main excitatory neurotransmitter in the CNS. 
The concentration of glutamate in the synaptic cleft is tightly 
regulated by the interplay between glutamate release and gluta-
mate clearance. Under disease conditions, abnormal glutamate 
release and/or dysfunction of glutamate clearance causes elevated 
extracellular glutamate concentrations. This results in overstimu-
lation of glutamate receptors, leading to neuronal injury or death, 
known as excitotoxicity (1), which has been implicated in a wide 
range of acute and chronic neurodegenerative diseases.
The glial glutamate transporter EAAT2 is found primarily 
on perisynaptic processes of astrocytes closely associated with 
excitatory synaptic contacts and is responsible for maintaining 
low extracellular glutamate concentrations (2–4). Loss of EAAT2 
protein and function is commonly found in chronic neurode-
generative diseases such as amyotrophic lateral sclerosis (ALS) 
and Alzheimer’s disease (AD) (5–7) and may be the main cause 
of excitotoxicity in these diseases. Restoration of EAAT2 protein 
levels and function may provide therapeutic benefit for these 
chronic diseases. In disease conditions such as epilepsy, stroke, 
and neurotrauma, an acute, dramatic increase in extracellular 
glutamate levels causes severe neuronal damage (8–10). Imme-
diate upregulation of EAAT2 protein will reduce extracellular 
glutamate levels and thereby prevent damage to neurons. 
Therefore, increased EAAT2 expression is a potential therapeu-
tic approach for preventing excitotoxicity for both chronic and 
acute neurodegenerative diseases.
EAAT2 can be upregulated by transcriptional (11–13) or transla-
tional (14) activation. Rothstein and colleagues discovered that many 
β-lactam antibiotics, such as ceftriaxone, are able to increase EAAT2 
protein levels through transcriptional activation (15). Our laborato-
ries previously executed high-throughput screenings to search for 
compounds that increase EAAT2 translation (16). We focused on 
translational activation, because (a) loss of EAAT2 protein in ALS or 
AD patients is most likely due to disturbances at the post-transcrip-
tional level, since EAAT2 mRNA is not decreased (6, 17); (b) greater 
selectivity may be achieved; and (c) immediately increasing EAAT2 
protein and function can be achieved, which is critical for an effec-
tive therapeutic response. This screening campaign resulted in the 
discovery of sixteen classes of compounds that can activate EAAT2 
translation. After intensive studies of these compounds, a pyridaz-
ine-based series was selected for further investigation, including 
a structure-activity relationship (SAR) study (18). Here, we report 
characterization and efficacy studies of a representative compound, 
LDN/OSU-0212320 (Figure 1A), from this lead series.
Results
LDN/OSU-0212320 increases EAAT2 expression through translational acti-
vation in a primary astrocyte cell line. PA-EAAT2 is a rat primary astro-
cyte line that does not express endogenous EAAT2 protein, but sta-
bly expresses human EAAT2 mRNAs driven by the CMV promoter 
(14). In the absence of serum, PA-EAAT2 cells express low amounts 
of EAAT2 protein, although the recombinant EAAT2 mRNAs are 
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expressed (translational silencing); however, EAAT2 protein levels 
are increased when an activator is added to the culture (translational 
activation). We previously used this cell line for high-throughput 
screening to identify EAAT2 translational activators (16). To prior-
itize candidate compounds, we initially evaluated the activation of 
EAAT2 protein in PA-EAAT2 cells. Promising compounds were fur-
ther evaluated in primary dissociated neuron and astrocyte mixed 
cultures and then in mice. Figure 1 presents the characterization 
of LDN/OSU-0212320 in PA-EAAT2 cells. LDN/OSU-0212320 
increased EAAT2 protein levels in a dose-dependent (Figure 1B; 
EC50 = 1.83 ± 0.27 μM) and time-dependent (Figure 1C) manner. 
Importantly, the induction occurred in a relatively short amount 
of time (within 2 hours) and was sustained even up to 72 hours 
(data not show). The induction was blocked by cycloheximide, 
an inhibitor of protein biosynthesis (data not shown). A [3H]glu-
tamate uptake assay demonstrated that glutamate uptake func-
tion correlated with increased EAAT2 protein levels (Figure 1D). 
Immunofluorescence staining and subcellular fractionation stud-
ies showed that induced EAAT2 protein was properly localized in 
the plasma membrane (Figure 1E). Quantitative real-time RT-PCR 
analysis revealed that EAAT2 mRNA levels were not changed by 
LDN/OSU-0212320 treatment (Figure 1F). Pulse-chase experi-
ments indicated that the rate of EAAT2 protein degradation was 
also not changed by compound treatment (Figure 1G). Polyribo-
some analysis showed that a large portion of EAAT2 mRNAs shifted 
from the translational silenced state (nonpolyribosomal fractions; 
black solid line in Figure 1H) to the actively translating state (poly-
ribosomal fractions; red solid line in Figure 1H) 1 hour after add-
ing LDN/OSU-0212320 to cultures, but the compound did not 
affect actin mRNA translation activity (dotted line in Figure 1H). 
Collectively, these data indicate that LDN/OSU-0212320 increased 
EAAT2 expression through translational activation.
LDN/OSU-0212320 protects cultured neurons from glutamate-mediated 
excitotoxic injury/death. We next evaluated LDN/OSU-0212320 in 
primary dissociated neuron and astrocyte mixed cultures. As shown 
in Figure 2, A and B, LDN/OSU-0212320 increased EAAT2 protein 
levels and glutamate uptake function, but did not affect EAAT1 or 
EAAT3 protein levels (data not shown). Significantly, when the cul-
tures were treated with glutamate for 2 hours to induce excitotoxic-
ity, the compound-treated cultures were protected. Figure 2C shows 
that glutamate-induced cytotoxicity, as assessed by lactate dehydro-
genase (LDH) assay, was significantly reduced in compound-treated 
cultures. Figure 2D shows that LDN/OSU-0212320 treatment mark-
edly prevented neuronal loss and degeneration, as assessed by MAP2 
immunostaining. On average, 14.6 ± 4.4% of MAP2-positive neu-
rons remained after 0.1 mM glutamate treatment when compared 
with the control, while pretreatment with compound at 2 or 3 μM 
significantly recovered this ratio to 40.4 ± 6.4% and 60.9 ± 7.3%, 
respectively (Figure 2E). These protective effects were partially abol-
ished by pretreatment with dihydrokainic acid (DHK), an EAAT2 
blocker, suggesting that activation of EAAT2 is involved in LDN/
OSU-0212320–mediated neuroprotection. Figure 2F shows MAP2 
immunolabeling and nuclear condensation (arrows) at a higher 
magnification. Furthermore, in all assays, LDN/OSU-0212320 
did not cause detectable toxicity. It is notable that similar protec-
tive effects were also observed in our previous EAAT2 transgenic 
mice study (19). The study found that primary dissociated cultures 
derived from EAAT2 transgenic mice could tolerate glutamate tox-
icity much better than cultures derived from nontransgenic mice. 
These studies indicate that increased expression of EAAT2 protects 
cells from glutamate-induced toxicity.
LDN/OSU-0212320 has adequate pharmacokinetic properties, good 
potency, and no observed toxicity in vivo. LDN/OSU-0212320 is com-
pliant with Lipinski rules and lacks functionality that would pre-
dict overt toxicity or reactivity. This compound has a low molecular 
weight of 293.38, a calculated logarithm of the octanol/water parti-
tion coefficient (cLogP) value of 3.28, and a polar surface area (PSA) 
value of 37.08 Å2 in the range typical of compounds that can pene-
trate the blood-brain barrier. However, the shortcomings of LDN/
OSU-0212320 include poor aqueous solubility (12 μM, pH 7.4) 
and a short half-life in mouse liver microsomes (t1/2 = 7 minutes). 
We conducted in vivo pharmacokinetic evaluation of LDN/OSU-
0212320 in male C57Bl/6 mice. After a single i.p. administration 
of LDN/OSU-0212320 (3 mg/kg), we determined the plasma and 
brain concentrations by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) over an 8-hour period (Figure 3A). 
LDN/OSU-0212320 reached an average maximum plasma con-
centration (Cmax) of 42.1 ± 3.6 ng/ml 15 minutes after injection. We 
estimated the plasma and brain half-lives to be 2.63 and 2.64 hours, 
respectively. The average brain/plasma ratio was approximately 2 
at all time points tested. These results indicate that LDN/OSU-
0212320 has adequate pharmacokinetic properties.
We determined the maximum tolerated dose (MTD) of LDN/
OSU-0212320 in male C57BL/6 mice. The study was conducted 
in two phases: (a) a single-dose tolerability study tested at doses of 
10, 25, 50, and 75 mg/kg i.p. (3 mice/dose); and (b) a 5-day repeat-
dose tolerability study tested at doses of 10, 25, 50, and 100 mg/kg 
i.p. (5 mice/dose). All animals were observed for clinical signs of 
toxicity each day of dosing. In the repeat-dose study, we determined 
body weights prior to each dose and prior to termination on day 6. 
We evaluated clinical pathologies including standard hematology, 
serum chemistry, and coagulation parameters in samples collected 
on day 6. All animals from phase II were necropsied, and selected 
organs were weighed. We observed no clinical signs of toxicity, 
adverse clinical pathological changes, or body weight changes rel-
Figure 1
Characterization of LDN/OSU-0212320 in PA-EAAT2 cells. (A) Struc-
ture of LDN/OSU-0212320. (B) Dose response experiments. Cells 
were treated with compound for 24 hours. EC50 = 1.83 ± 0.27 μM. n = 5. 
(C) Time course experiments. Cells were treated with compound at 
10 μM. Compound increased EAAT2 protein levels in a short amount of 
time. (D) [3H] glutamate uptake experiments. Glutamate uptake activity 
correlated with increased EAAT2 protein levels. Cells were treated with 
compound for 24 hours. n = 6. (E) Immunofluorescence staining and 
subcellular fractionation analysis. Induced EAAT2 was properly local-
ized in the plasma membrane. Cells were treated with compound at a 
concentration of 3.3 μM for 24 hours. M, plasma membrane fraction. 
C, cytosolic fraction. Scale bar: 25 μm. (F) Real-time RT-PCR analysis. 
Compound treatment did not increase EAAT2 mRNA levels. Cells were 
treated with compound at a concentration of 10 μM for 6, 18, 24, and 
48 hours. Results after 24 hours are shown. n = 5. (G) Pulse-chase 
analysis. Compound treatment did not affect the rate of EAAT2 protein 
degradation. Cells were preincubated with sulfo-NHS-SS-biotin to label 
surface EAAT2 proteins and were then treated with compound (10 μM). 
Cells were harvested at 8 and 24 hours to measure biotin-labeled 
EAAT2 protein levels. Equal protein loading was confirmed by Ponceau 
S staining. (H) Polyribosome analysis. Compound treatment increased 
EAAT2 mRNA translation activity. Cells were treated with compound 
at a concentration of 10 μM for 1 hour. Cell lysates were prepared and 
fractionated by a 15% to 60% sucrose gradient. RNAs were extracted 
from each fraction and analyzed by real-time RT-PCR. n = 4. **P < 0.01.
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ative to controls at the end of dosing. Due to a lack of toxicity, the 
highest dose tested, 100 mg/kg/day, was determined to be the 5-day 
no observed adverse effect level (NOAEL) for LDN/OSU-0212320.
We next examined EAAT2 protein levels and glutamate uptake 
activities in brain following i.p. administration of LDN/OSU-
0212320 to C57BL/6 mice. Plasma membrane vesicles were pre-
pared from mouse forebrains to measure functional EAAT2 pro-
tein. After a single i.p. 40-mg/kg dose of LDN/OSU-0212320, 
EAAT2 protein levels and associated glutamate uptake increased 
by approximately 1.5- to 2-fold at 2 hours and by approximately 2- 
to 3-fold between 8 and 24 hours after injection (Figure 3B). Even 
72 hours after injection, an approximately 1.5-fold increase in EAAT2 
protein levels could still be detected (data not shown). In addition, 
we found that LDN/OSU-0212320–induced EAAT2 protein levels 
and glutamate uptake were dose dependent (Figure 3C). This induc-
tion was not due to transcriptional activation, because Eaat2 mRNA 
Figure 2
Characterization of LDN/OSU-0212320 in primary dissociated neuron and astrocyte mixed cultures. Seven-day-old primary cultures were treated 
with the indicated doses of compound for 24 hours and then harvested for analyses. (A) Western blot analysis shows that compound increased 
EAAT2 expression in a dose-dependent manner. (B) [3H] glutamate uptake assay shows a dose-dependently increased glutamate uptake. n = 6. 
(C) Cultures were insulted with 0.5 mM glutamate for 2 hours to induce excitotoxicity. LDH assay shows a dose-dependent reduction of LDH 
release in compound-treated cultures. n = 6. (D) MAP2 immunostaining shows that compound treatment significantly prevented glutamate-
mediated neuronal loss and degeneration. The protections were partially abolished by pretreatment of DHK (100 μM). Cultures were exposed to 
0.1 mM glutamate for 2 hours. Scale bar: 50 μm. (E) Quantitative analysis of MAP2-positive neurons. MAP2-positive neurons were counted and 
quantified as described in the Methods. n = 15. (F) MAP2-immunolabeled neurons and their nuclear morphology (Hoechst 33342 staining) at a 
higher magnification. Arrows point to the corresponding neurons of the highlighted nuclei. Scale bar: 25 μm. *P < 0.05; **P < 0.01; ***P < 0.001.
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was not increased, as measured by quantitative real-time RT-PCR 
(Figure 3D). Polyribosomal analysis indicated that LDN/OSU-
0212320 increased Eaat2 mRNA translation activity (Figure 3E), but 
did not affect actin mRNA translation activity (data not shown). 
We compared ceftriaxone (200 mg/kg), which increases EAAT2 
expression through transcriptional activation (13, 15), with LDN/
OSU-0212320 (40 mg/kg), which activates EAAT2 translation. As 
shown in Figure 3F, LDN/OSU-0212320 had greater EAAT2 induc-
tion than did ceftriaxone (a single dose after 24 hours). These results 
indicate that LDN/OSU-0212320 has good potency in vivo.
To assess the biological activity and selectivity of  LDN/OSU-
0212320, we performed an in vitro side–effect profiling study. We 
tested 71 targets at 10 μM in duplicate. These targets included 
30 neurotransmitter-related receptors, 2 steroids, 6 ion channels, 
1 second messenger, 3 prostaglandins, 4 growth factors/hormones, 
13 brain/gut peptides, 5 enzymes, and 7 cytochrome p450. The 
results showed that LDN/OSU-0212320 had 69% inhibition on the 
cytochrome p450 CYP1A2 and 43% inhibition on calcium chan-
nel L–type at 10 μM. All other targets demonstrated less than 30% 
inhibition at 10 μM (Supplemental Table 1; supplemental material 
available online with this article; doi:10.1172/JCI66163DS1). Addi-
tionally, we performed a protein kinase–profiling study. We tested 
LDN/OSU-0212320 at 1 and 10 μM against 230 kinases. The results 
showed that EPHA4 and EPHA5 were inhibited by 44% at 10 μM. 
Figure 3
Evaluation of LDN/OSU-0212320 in WT mice. (A) Pharmacokinetic studies. After administration of a single i.p. dose of compound (3 mg/kg) to 
mice, plasma and brain concentrations were determined (n = 3/time point). Cmax = 42.1 ± 3.6 ng/l at 15 minutes, plasma t1/2 = 2.63 hours, brain 
t1/2 = 2.64 hours. (B) Time course studies. After a single dose of compound (40 mg/kg), the brains were harvested at the indicated times (n = 3/time 
point). Plasma membrane vesicles were prepared from forebrains to determine EAAT2 protein levels and measure [3H] glutamate uptake activity. 
Increased EAAT2 could be detected as early as 2 hours after injection. (C) Dose response studies. Mice received a single dose of compound 
(n = 3/dose), and brains were harvested at 24 hours after injection. Compound dose-dependently increased EAAT2 levels and glutamate uptake. 
(D) Quantitative real-time RT-PCR analysis. Eaat2 mRNA levels were not changed by compound treatment. Mice received compound (40 mg/kg), 
and brains were harvested at 8 and 24 hours. Results at 8 hours are shown. n = 5. (E) Polyribosome analysis. Compound treatment increased 
Eaat2 mRNA translation activity. Mice received compound (40 mg/kg), and brains were harvested at 1 hour. n = 4. (F) Comparison of ceftriaxone 
(Ceftri) and LDN/OSU-0212320. Mice received a single dose of ceftriaxone (200 mg/kg) or LDN/OSU-0212320 (40 mg/kg) (n = 3 each), and 
brains were harvested at 24 hours. LDN/OSU-0212320 is more potent than ceftriaxone. (G) Western blot analysis of other protein expression 
levels in LDN/OSU-0212320–treated (40 mg/kg) brains. LDN/OSU-0212320 did not induce global protein synthesis. *P < 0.05.
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All other kinases tested showed insignificant activity (Supplemen-
tal Table 2). These studies indicate that LDN/OSU-0212320 has 
high specificity and low side effect/toxicity potential.
Furthermore, the following observations indicate that the effects 
of LDN/OSU-0212320 on EAAT2 protein expression were not due 
to a general increase in protein synthesis. First, the total amount of 
protein in compound-treated cells and mice was not increased com-
pared with that in vehicle-treated cells and mice. Second, we exam-
ined the expression of a variety of other proteins in mouse brains: 
astrocyte-specific proteins including GFAP, glutamine synthetase 
(GS), and EAAT1 (another astrocytic glutamate transporter subtype); 
several housekeeping proteins including GAPDH, SOD1, actin, YB-1, 
and RNA polymerase II; several neuron-specific proteins including 
synaptophysin, EAAT3 (a neuronal glutamate transporter), EAAT4, 
PSD95, NMDA receptor subunit NR2B, and vesicular glutamate 
transporter 1 (VGLUT1); and several signaling proteins including 
Figure 4
LDN/OSU-0212320 delays motor function decline and extends lifespan in SOD1(G93A) mice. SOD1(G93A) mice received compound daily (i.p., 
40 mg/kg) starting at 84 days of age (indicated by arrows in the figure) until death. (A) Motor function decline as assessed by grip strength mea-
surement. Data were analyzed using dynamic fitting nonlinear regression analysis. The average number of days until a 50% grip strength decline 
occurred is indicated. (B) Survival results. Data were analyzed using Kaplan-Meier survival analysis. The average number of days of survival is 
indicated. (C) Body weight change. The average number of days until a 10% decline in initial body weight occurred is indicated. (D) Representative 
female mice at 126 days old. (E) Representative images showing cresyl violet staining and EAAT2 immunostaining of the ventral horn region of 
the spinal cord from 120-day-old female mice. Scale bar: 50 μm. (F) Western blot results show that LDN/OSU-0212320 restores EAAT2 protein 
levels. Spinal cords from 120-day-old mice were analyzed. Six animals in each group were analyzed for E and F.
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AKT, PI3K, IKB-α, and ERK2. None of the above proteins were 
induced by LDN/OSU-0212320 (Figure 3G), suggesting that LDN/
OSU-0212320 did not induce global protein synthesis.
LDN/OSU-0212320 slows disease progression and extends the lifespan of 
SOD1(G93A) mice. Transgenic mice expressing familiar ALS-linked 
mutant superoxide dismutase (SOD1) have been commonly used 
for ALS preclinical trials. The SOD1(G93A) mouse, in particular, the 
high copy number line, has been the most commonly used trans-
genic mouse model in ALS preclinical trials (20–22). SOD1(G93A) 
mice exhibit loss of motor neurons and associated motor functions 
starting at approximately 80 to 90 days of age and die at approxi-
mately 4 to 5 months of age. Mice begin to lose EAAT2 protein in 
the spinal cord at approximately 80 to 90 days of age, and EAAT2 
protein levels gradually decrease with disease progression. We pre-
viously crossed EAAT2 transgenic mice, which have a 1.5- to 2-fold 
increase in EAAT2 protein levels, with SOD1(G93A) mice and found 
that increased EAAT2 expression delayed disease onset, but not the 
survival of mice (19). Furthermore, Rothstein et al. reported that 
treating SOD1(G93A) mice with ceftriaxone (200 mg/kg) markedly 
ameliorated symptoms and prolonged survival (15).
To determine whether translational activation of EAAT2 was 
protective in a mouse model of ALS, we evaluated the effects of 
LDN/OSU-0212320 in the SOD1(G93A) mouse. Several prelim-
inary experiments were conducted. First, to ensure that LDN/
OSU-0212320 could restore EAAT2 protein levels in SOD1(G93A) 
mice, we administered compound by intrathecal injection into 
Figure 5
LDN/OSU-0212320 reduces mortality rate, chronic seizure, and neuronal death following pilocarpine-induced SE. Mice received compound (i.p., 
40 mg/kg) and were treated with pilocarpine 3 hours later. Mice that reached SE received compound daily, and chronic seizures were recorded 
4 weeks after SE for a 2-week period (15 independent experiments in a total of 153 vehicle- and 152 compound-treated mice). (A) Acute seizure sever-
ity (maximal seizure activity of each animal within 2 hours after pilocarpine injection). The percentage of mice that reached each seizure stage did not 
differ between the two groups. (B) Latency (time interval between pilocarpine injection and the indicated stage). Latency did not differ between the two 
groups. (C) Mortality rate (percentage of mice that died in each experiment, n = 15). A significant decrease was observed in the compound-treated 
group on days 7 and 60 after SE. (D–F) Spontaneous recurrent seizures. (D) Percentage of mice (vehicle, n = 19; compound, n = 25) that developed <1, 
1~2, 2~3, or >3 stage V seizures in an 8-hour period. (E) Average number of stage V seizures in an 8-hour period. (F) Frequency of stage V seizures 
during each day of recording. Chronic seizure frequency was significantly reduced in compound-treated mice. Arrows indicate that a mouse died on 
that day. (G and H) Hippocampal damage. Nine sets of brains 8 weeks after SE were analyzed with cresyl violet staining (15–20 sections/mouse). 
(G) Representative images of the dentate hilus. Scale bar: 20 μm. (H) Quantitative analysis of hilar cells. Compound treatment significantly attenuated 
cell damage. (I) A strong positive correlation was detected between hilar cell loss and chronic seizure frequency. *P < 0.05.
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the lumbar region of the spinal cord of 110-day-old mice (10 mM, 
3 injections of 5 μl/injection/day). The results showed that LDN/
OSU-0212320 was able to restore EAAT2 protein levels and func-
tion in the disease stage in SOD1(G93A) mice (data not shown). 
Second, to select a dose for long-term studies, we tested two doses of 
LDN/OSU-0212320 (10 and 40 mg/kg) by daily i.p. administration 
(n = 6 per group) starting at 84 days of age, when the mice had lost 
approximately 10% to 15% of their motor function (the early symp-
tomatic stage), which may be equivalent to the stage at which ALS 
patients first visit a doctor. We observed that the dose of 10 mg/kg 
had no effect on disease onset (as assessed by motor function decline 
described below), but extended survival by approximately 11 days. 
We found that the 40 mg/kg dose had better effects: delayed motor 
function decline for approximately 11 days and prolonged survival 
Figure 6
LDN/OSU-0212320 treatment results in activation of PKC, which subsequently activates YB-1, leading to enhancement of EAAT2 translation. 
(A) Depletion of YB-1 by siRNA reduced compound-induced EAAT2 expression in PA-EAAT2 cells. Cells were transfected with YB-1 siRNA and 
were treated 24 hours later with compound (10 μM) for 24 hours. Lanes were run on the same gel but were noncontiguous. (B) Increased YB-1-
EAAT2 mRNA interaction following compound treatment. PA-EAAT2 cells were treated with compound (10 μM) for 2 hours and then harvested for 
immunoprecipitation (anti–YB-1 antibodies). Coimmunoprecipitated EAAT2 mRNAs were quantified by real-time RT-PCR. Mice received a single 
dose of compound (40 mg/kg, i.p.), and brains were harvested at 2 hours for immunoprecipitation. n = 5. (C) Compound increased YB-1 phospho-
rylation (p-YB-1). PA-EAAT2 cells: 10 μM compound. Mouse brain: 40 mg/kg, harvested at 1 hour. (D) PKC inhibitors blocked compound-induced 
EAAT2 expression in PA-EAAT2 cells. Cells were pretreated with inhibitors for 1 hour and then treated with compound (10 μM) for 24 hours. 
(E) PKC inhibitors blocked compound-induced YB-1 phosphorylation in PA-EAAT2 cells. (F) PMA increased YB-1 phosphorylation concomitantly 
with PKC phosphorylation (p-PKC). Increased EAAT2 protein levels were not observed until 8 hours after treatment. (G) Compound increased 
PKC phosphorylation. PA-EAAT2 cells: 10 μM compound. Mouse brain: 40 mg/kg, harvested at 1 hour. (H) Compounds of different potencies 
were examined for their effects on PKC activation. p-PKC levels are highly correlated with EAAT2 induction levels. Each data point represents 
the mean of three experiments. ***P < 0.001.
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for approximately 12 days. Third, to ensure that 40 mg/kg is a safe 
dose for long-term treatment, we treated WT mice at this dose for 
2 months. We observed that LDN/OSU-0212320–treated mice (n = 6) 
exhibited behavior similar to that of nontreated mice (n = 6). We 
observed no differences in body weight between compound-treated 
and nontreated mice. Immunohistochemical characterization of the 
brains revealed that long-term treatment did not cause neuronal 
loss (as assessed by cresyl violet staining and nuclear staining), astro-
glial activation (as assessed by GFAP immunostaining), or micro-
glial activation (as assessed by CD11b immunostaining) (Supple-
mental Figure 1). We found that LDN/OSU-0212320 did not cause 
adverse effects after long-term treatment in mice.
We then evaluated the effects of LDN/OSU-0212320 in 
SOD1(G93A) mice at 40 mg/kg in detail. We treated the mice with 
compound from the age of 84 days until death. LDN/OSU-0212320–
treated (females, n = 23; males, n = 22) and vehicle-treated (females, 
n = 18; males, n = 21) animals were monitored three times per week 
for motor function by measuring grip strength and were also moni-
tored for survival and body weight. The results showed that in female 
mice, compound treatment significantly delayed motor function 
decline by approximately 14 days (50% grip strength: vehicle, 108 days 
vs. compound, 122 days) (Figure 4A), prolonged overall survival 
by approximately 15 days (vehicle, 126.8 ± 2.4 days vs. compound, 
141.1 ± 1.5 days; P < 0.001, Kaplan-Meier survival analysis with log-
rank test) (Figure 4B), and delayed body weight decline by approx-
imately 19 days (10% body weight loss: vehicle, 112 days vs. com-
pound, 131 days) (Figure 4C). These effects were not as significant 
in male mice, which showed a difference in delayed motor function 
decline of approximately 12 days (vehicle, 103 days vs. compound, 
115 days), a difference in prolonged survival of approximately 10 days 
(vehicle, 123.4 ± 2.4 days vs. compound, 133.2 ± 2.8 days; P = 0.013, 
Kaplan-Meier survival analysis with log-rank test), and a difference 
in delayed body weight decline of 6 days (vehicle, 113 days vs. com-
pound, 119 days) (Figure 4, A–C). This difference between the sexes 
may be due to an earlier onset of disease symptoms in male mice that 
required earlier treatment in order to be equivalent to the results seen 
in the females. Figure 4D shows representative female mice at 126 days 
old. Figure 4, E and F, shows that LDN/OSU-0212320 restores 
EAAT2 protein levels and partially protects motor neurons from 
degeneration. These results indicate that LDN/OSU-0212320 has 
marked protective effects in this ALS disease model.
LDN/OSU-0212320 reduces mortality, spontaneous recurrent seizure, 
and neuronal death in a pilocarpine-induced status epilepticus mouse 
model. Several lines of evidence suggest that high extracellular glu-
tamate levels play a crucial role in seizure initiation and propaga-
tion (23–28). We previously investigated pilocarpine-induced sta-
tus epilepticus (SE) in EAAT2 transgenic mice and observed that 
increased EAAT2 expression significantly prevented SE-induced 
neuronal death, epileptogenesis, and subsequent recurrent sei-
zures (29). We evaluated the effects of LDN/OSU-0212320 in this 
epilepsy model by first testing two doses of LDN/OSU-0212320, 
20 and 40 mg/kg, in male FVB mice (n = 16 per group). In order to 
evaluate the effects of LDN/OSU-0212320 on early acute seizure 
activity and later chronic seizure activity, we pretreated mice with 
compound prior to induction of seizures with pilocarpine. We 
observed dose-dependent protection against SE-induced neuronal 
death and recurrent seizures. We have previously demonstrated 
that a 2-month administration of 40 mg/kg LDN/OSU-0212320 
did not cause overt toxicity or adverse effects (Supplemental Fig-
ure 1). Therefore, this dose was used in the following studies.
Littermate-matched mice received 40 mg/kg of compound or vehi-
cle by i.p. injection. Three hours later, the mice received pilocarpine 
to induce seizures and were observed for 2 hours to record acute sei-
zure severity and the latency period. The Racine scale was used to rate 
seizure severity (stages I, II, III, IV, V, and SE). Fifteen independent 
experiments (~20 animals in each experiment) were performed with 
a total of 152 LDN/OSU-0212320–treated and 153 vehicle-treated 
male mice. We observed that the percentage of mice that reached each 
seizure stage (seizure severity) was not significantly different between 
the compound group and the vehicle group (Figure 5A; P = 0.339, 
χ2 test). Latency, which was the time interval between the pilocarpine 
injection and each seizure stage, was also not significantly different 
between the two groups (Figure 5B; stage III: P = 0.86; SE: P = 0.70; 
Mann-Whitney rank sum test), suggesting that LDN/OSU-0212320 
has no significant effects on early acute seizure activity.
Mice that reached SE and maintained tonic limb extension for 
at least 60 minutes were used for subsequent studies. We further 
treated the mice with 40 mg/kg/day of compound until euthanized 
for studies. We observed several striking phenomena. The mortality 
rate after SE is an important parameter for evaluation of antiepilep-
tic effects. As shown in Figure 5C, there was no obvious difference 
in mortality rates between compound and vehicle groups on the 
day that SE was induced. However, the mortality rates were signifi-
cantly decreased in the compound treatment group compared with 
those in the vehicle treatment group on day 7 after SE (vehicle, 82 
of 153 vs. compound, 51 of 152; P = 0.03, χ2 test) and also on day 60 
after SE (vehicle, 53 of 90 vs. compound, 33 of 90; P = 0.005, χ2 test).
SE can cause complex molecular, biochemical, and structural 
changes in the brain, which over time result in the development of 
spontaneous recurrent seizures. We monitored SE-induced chronic 
seizures by video recording to determine the frequency and severity of 
seizure activity. Mice were monitored for 2 weeks (8 hours/day) start-
ing 4 weeks after SE, and the average frequency of stage V seizures 
that occurred in an 8-hour period in each mouse was quantified. Six 
of 19 vehicle-treated mice and 2 of 25 compound-treated mice died 
during the recording period (Figure 5F, arrows). Compound-treated 
mice developed fewer stage V seizures (Figure 5D). The average sei-
zure (stage V) frequency in compound-treated mice (1.14 ± 0.21) was 
reduced by about half of that observed in vehicle-treated littermates 
(2.03 ± 0.37; P = 0.025, Student’s t test) (Figure 5E). The repeated mea-
surements of stage V seizure frequency during the recording period 
were analyzed using generalized linear mixed-effects models with a 
log link function. We included a random intercept term to account for 
the within-subject correlation between repeated measures. There was 
a significant difference between the compound group and the vehicle 
group in terms of stage V seizure occurrence over time (Figure 5F); 
specifically, LDN/OSU-0212320 treatment tended to reduce the sei-
zure occurrence number by 1.0961 on average (P = 0.012).
Finally, intense seizure activity associated with SE causes signifi-
cant neuronal degeneration in hippocampal regions. We examined 
hippocampal damage 8 weeks after SE, when chronic seizures had 
developed. Coronal sections were stained with cresyl violet to iden-
tify live cells. We observed SE-induced neuronal death in several 
hippocampal subregions, including CA1, CA3, and the dentate 
hilus in both compound- and vehicle-treated brains; however, 
there was an overall significant reduction of neuronal death in 
the compound-treated brains. Hilus interneurons were the most 
vulnerable after SE. Representative images of the dentate hilus are 
shown in Figure 5G. We counted the live hilar cells under a light 
microscope. On average, there were about 39.0 ± 1.2 neurons per 
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section in the hilus of control mice (no SE), while only 7.3 ± 0.5 
neurons were alive in vehicle-treated mice after SE. We observed 
a significant increase in neuronal survival (21.4 ± 4.6 neurons 
per section) in compound-treated mice (Figure 5H; P < 0.05). A 
strong positive correlation was detected between hilar cell loss and 
chronic seizure frequency (Figure 5I; correlation coefficient = 0.68, 
P < 0.001, Spearman’s rank order correlation test). Taken together, 
the above studies indicate that LDN/OSU-0212320 is able to sig-
nificantly reduce SE-induced mortality, spontaneous recurrent 
seizure, and neuronal death. We did not observe these protective 
effects in the inactive compound LDN/OSU-0213825, which has 
a structure similar to that of LDN/OSU-0212320, but cannot 
increase EAAT2 protein levels (Supplemental Figure 2).
LDN/OSU-0212320 treatment results in activation of PKC and subsequent 
YB-1 activation, which regulates enhancement of EAAT2 translation. Y-box–
binding protein 1 (YB-1) is a multifunctional protein that binds DNA 
and RNA and plays an important role in transcriptional and transla-
tional regulation (30, 31). A recent study indicated that YB-1 interacts 
with Eaat2 mRNAs in the mouse brain (32). To examine whether YB-1 
is involved in compound-activated EAAT2 translation, we performed 
siRNA knockdown experiments and found that depletion of YB-1 
markedly reduced LDN/OSU-0212320–induced EAAT2 expression 
in PA-EAAT2 cells (Figure 6A). We then examined whether LDN/
OSU-0212320 altered YB-1 and EAAT2 mRNA interaction. YB-1 pro-
teins were immunoprecipitated with anti–YB-1 antibodies, and the 
coimmunoprecipitated EAAT2 mRNAs were quantified by real-time 
RT-PCR. The results showed a significant increase in EAAT2 mRNA 
associated with YB-1 in PA-EAAT2 cells 2 hours after adding LDN/
OSU-0212320, but not in the inactive compound–treated (LDN/
OSU-0213825–treated) cells (Figure 6B). We also found increased 
YB-1-EAAT2 mRNA interaction in mouse brains 2 hours after i.p. 
injection of LDN/OSU-0212320 in mice, but not in mice injected 
with inactive compound (Figure 6B). Furthermore, we found that 
LDN/OSU-0212320 increased YB-1 phosphorylation at the Ser102 
site in PA-EAAT2 cells within 30 minutes of adding compound 
(Figure 6C). We also observed increased YB-1 phosphorylation in 
mouse brains within 1 hour of i.p. injection in mice with LDN/OSU-
0212320 (Figure 6C). The inactive compound (LDN/OSU-0213825) 
did not increase YB-1 phosphorylation (data not shown).
To identify the signaling pathways involved in compound-acti-
vated YB-1 phosphorylation and subsequent EAAT2 translation, 
we performed inhibition studies in PA-EAAT2 cells. We found that 
protein kinase C (PKC) inhibitors GF109203X and Gö6976 blocked 
both EAAT2 induction in a dose-dependent manner (Figure 6D) 
and YB-1 phosphorylation (Figure 6E). However, GF109203X and 
Gö6976 are known to inhibit two other kinases, RSK2 and p70S6 
kinase (33). RSK2 is regulated by the MEK/ERK pathway, and p70S6 
kinase is regulated by the mTOR pathway. We examined whether 
U-0126, an MEK inhibitor, and rapamycin, an mTOR inhibitor, 
blocked LDN/OSU-0212320–activated EAAT2 expression. The 
results showed that neither U-0126 nor rapamycin affected EAAT2 
induction (data not shown). We then investigated whether PMA 
(phorbol-12-myristate-13-acetate), a PKC activating agent, could 
induce EAAT2 expression. The results showed that PMA increased 
YB-1 phosphorylation concomitantly with PKC phosphorylation 
within 30 minutes (Figure 6F). However, increased EAAT2 protein 
levels were not observed until 8 hours after treatment (Figure 6F), 
unlike LDN/OSU-0212320, which could induce EAAT2 expression 
within 2 hours (Figure 1C). These results indicate that other factors 
induced by the compound are needed for rapid EAAT2 induction.
The PKC family consists of fifteen isozymes. GF109203X inhibits 
PKCα, β1, δ, ε, and ζ (IC50 = 0.008, 0.018, 0.210, 0.132, and 5.8 μM, 
respectively). Gö6976 inhibits PKCα and β1 (IC50 = 2.3 and 6.2 nM, 
respectively), suggesting that either PKCα or β1 is involved in the 
activation process. To determine the isozyme that may be involved, 
we tested another PKC inhibitor, Gö6983, which inhibits PKC α, β, 
γ, δ, and ζ (IC50 = 7, 7, 6, 10, and 60 nM, respectively), but not β1, 
and found that this inhibitor did not affect compound-activated 
YB-1 phosphorylation or EAAT2 expression (data not shown). 
These results suggest that PKC β1 is involved in LDN/OSU-
0212320–activated EAAT2 expression. PKC is phosphorylated at 
three sites in vivo (34). An autophosphorylation on a carboxyl ter-
minus serine residue (e.g., Ser661 in β1) regulates the PKC’s plasma 
membrane localization (34), where it interacts with diacylglycerol 
(DAG) and is transformed into a fully active enzyme. To further 
support the activation of PKC, we used phosphorylated PKC anti-
bodies that detect PKC only when phosphorylated at the carboxyl 
terminus serine residue (e.g., Ser661 in β1). The results showed 
that LDN/OSU-0212320 increased serine phosphorylation within 
15 minutes after addition to PA-EAAT2 cells (Figure 6F). We did 
not observe this increase in the presence of GF109203X or Gö6976 
(data not shown). Increased serine phosphorylation was also found 
in mouse brains within 1 hour after i.p. injection of LDN/OSU-
0212320 (Figure 6G). The inactive compound LDN/OSU-0213825 
did not increase PKC phosphorylation (data not shown). To fur-
ther confirm that PKC activation is related to EAAT2 induction, we 
examined serine phosphorylation levels in PA-EAAT2 cells treated 
with compounds of different potencies. The results showed that 
phosphorylated PKC levels are highly correlated with EAAT2 induc-
tion levels (Figure 6H; correlation coefficient = 0.9, P = 0.0015). 
These results indicate that LDN/OSU-0212320 treatment results 
in the activation of PKC, which subsequently stimulates YB-1, lead-
ing to enhancement of EAAT2 translation.
Discussion
The results reported here show that increased EAAT2 expres-
sion via translational activation by LDN/OSU-0212320 prevents 
excitotoxicity and provides substantial beneficial effects in ALS 
and epilepsy animal models. These results also suggest that our 
novel approach has therapeutic potential for both acute and 
chronic neurodegenerative diseases.
Memantine and riluzole are currently marketed drugs that have 
antiexcitotoxic properties. Memantine is a noncompetitive NMDA 
receptor antagonist and has been shown to have mild clinically 
relevant effects in moderate-to-severe AD (35). Riluzole inhibits 
the release of glutamate and also blocks some of the postsynap-
tic effects of glutamate (36). Riluzole is the only approved phar-
macologic treatment for ALS that prolongs survival by about 2 
to 3 months (37). Furthermore, ceftriaxone is an FDA-approved 
β-lactam antibiotic that can increase EAAT2 expression via the 
transcriptional activation mechanism (13, 15). A large clinical 
trial was undertaken recently to test ceftriaxone in ALS patients, 
but was stopped because predetermined criteria for efficacy were 
not met (38). This disappointing outcome raises a concern about 
whether increased EAAT2 expression can provide beneficial effects 
in humans. In our opinion, there are several reasons why this 
EAAT2 activation approach should not be disregarded. First, it is 
uncertain whether ceftriaxone is able to effectively increase EAAT2 
expression. While there is a body of evidence for ceftriaxone’s 
neuroprotection in vivo that is assumed to be a consequence of 
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At present, none of the marketed drugs have been found to atten-
uate the progression of epileptogenesis. Future studies will apply 
treatment after SE to further validate the antiepileptogenic effects.
Mechanism studies confirmed that LDN/OSU-0212320 did not 
affect EAAT2 mRNA levels or EAAT2 protein lifespan, but rather acti-
vate EAAT2 translational activity. We found that YB-1 contributes 
to compound-activated EAAT2 translation, although the detailed 
mechanism of how YB-1 regulates EAAT2 translation remains to be 
elucidated. LDN/OSU-0212320 treatment resulted in activation of 
PKC, probably the PKC β1 isozyme, which subsequently activates 
YB-1. Efforts to more clearly define the precise molecular mecha-
nisms of compound-mediated PKC activation, including identifying 
the compound targets, are currently under investigation.
The continuous optimization of LDN/OSU-0212320, other pyri-
dazine-based derivatives, or other structurally distinct enhancers 
of EAAT2 translation may lead to improved analogs for human 
clinical trials. In addition, it is worthwhile to test LDN/OSU-
0212320 or its analog in other disease models, in which excitotox-
icity has been shown to contribute to neurodegeneration such as 
AD and cerebral ischemia. Furthermore, understanding the molec-
ular mechanisms underlying the activation of EAAT2 translation 
by LDN/OSU-0212320 is also very important for advancing this 
therapeutic approach.
Methods
Animals. Mice were housed in a 12-hour light/12-hour dark cycle with free 
access to food and water. All experiments were approved by the IACUC 
of the Ohio State University and were conducted within the terms of the 
NIH guidelines for the care and use of laboratory animals. SOD1(G93A) 
transgenic mice (B6SJL-Tg [SOD1-G93A] 1Gur with a high copy number 
of the mutant human SOD1 gene) and FVB mice were purchased from 
The Jackson Laboratory. Transgenic SOD1(G93A) hemizygotes were 
maintained by mating transgenic males with B6SJLF1/J hybrid females. 
Transgenic offspring genotypes were determined by PCR using genomic 
DNA extracted from tail biopsies.
PA-EAAT2 cell studies. PA-EAAT2 cells were grown in DMEM (Invitrogen) 
supple mented with 10% FBS, 700 μg/ml geneticin (Gibco) and 100 μg/ml peni-
cillin-streptomycin (Sigma-Aldrich). Cells were maintained at 37°C in the pres-
ence of 5% CO2. To evaluate compound effects, cells were cultured in DMEM 
and treated with compound for the indicated times (Figure 1 and Figure 6) 
and then harvested for analysis. Western blotting (16), [3H]glutamate uptake 
assays (16), immunofluorescence staining (16), real-time RT-PCR (16), pulse-
chase analysis (14), polyribosome analysis (48), and subcellular fractionation 
analysis (49) were performed as described in our previous studies.
Primary dissociated culture studies. Primary dissociated neuron and astro-
cyte mixed cultures were prepared from newborn (12- to 24-hour-old) FVB 
WT pups as previously described (50). These cultures were maintained in 
DMEM and supple mented with 0.5% FBS, 100 μg/ml penicillin-strepto-
mycin, and 1X B-27 (Invitrogen) until use. To evaluate compound effects, 
cells were cultured in DMEM and treated with compound and/or 100 μM 
glutamate for the indicated times (Figure 2) and then harvested for analy-
sis. Western blotting, [3H]glutamate uptake assays, immunofluorescence 
staining, and LDH assays were performed as previously described (16, 19). 
For the immunofluorescence staining study, images were obtained using a 
Zeiss Axioskop 2 upright microscope and AxioVision software. The MAP2- 
positive cells with unambiguous neuronal morphology were counted using 
images at ×200 magnification. Ten random fields per well were counted to 
achieve an average MAP2-positive neuron number/mm2 per treatment in 
every experiment that was repeated five times. The MAP2-positive neuron 
count/mm2 in the no-treatment control was considered 100%.
EAAT2 upregulation, we note that not all studies have confirmed 
that EAAT2 can be upregulated by ceftriaxone (39, 40). Similarly, 
our study found only marginal upregulation of EAAT2 with cef-
triaxone administration to mice (Figure 3F). Second, there is dis-
crepancy in the literature regarding the efficacy of ceftriaxone in 
SOD1(G93A) mice. The original paper by Rothstein et al. showed 
that ceftriaxone treatment slowed disease progression and pro-
longed survival of SOD1(G93A) mice (15). However, Scott et al. 
retested ceftriaxone in SOD1(G93A) mice using an optimal study 
design and found no survival benefit (41). Kong et al. also reported 
no beneficial effects of ceftriaxone in SOD1(G93A) mice (42). 
Third, it is unknown whether EAAT2 protein levels and glutamate 
uptake function were restored in the ALS patients who received 
ceftriaxone in the clinical trial. In our opinion, the question as to 
whether increased EAAT2 provides beneficial effects in humans 
remains inadequately answered.
In comparison with ceftriaxone, LDN/OSU-0212320 has several 
advantages: (a) better physical-chemical properties for the treat-
ment of CNS diseases (LDN/OSU-0212320 has a lower molecular 
weight, fewer hydrogen bond donors and acceptors, a lower PSA, a 
higher cLogP value, and fewer rotatable bonds, all of which should 
result in significantly better brain penetration); (b) better potency 
(as shown in Figure 3F); (c) capacity to restore EAAT2 protein 
levels in SOD1(G93A) mice at a more advanced disease stage (as 
described above); (d) ability to increase EAAT2 levels more quickly, 
e.g., within 2 hours (Figure 3B) as compared with ceftriaxone, 
which requires 24–48 hours (15).
We found that LDN/OSU-0212320 was able to significantly 
delay motor function decline (females by ~14 days, males by ~12 
days) and extend the lifespan of SOD1(G93A) mice (females by 
~15 days, males by ~10 days). This study followed the guidelines 
established by the ENMC Group (43), which included the use of 
B6SJL hybrid SOD1(G93A) mice, gender-matched mice, litter-
mate-matched mice, and mice with the same copy number of the 
SOD1 transgene. Gurney et al. reported that treatment with rilu-
zole at dosages of 24 and 44 mg/kg beginning at 42 days of age 
(before the onset of clinical symptoms) extended the survival of 
SOD1(G93A) mice by about 2 weeks (44). Although many thera-
peutic agents that show beneficial effects in mutant SOD1 mice 
are unsuccessful in human trials, SOD1 mice remain the primary 
preclinical animal model for ALS. These mouse models recapit-
ulate several key features of ALS. Based on the results reported 
herein, enhancers of EAAT2 translation warrant further investiga-
tion as potential therapeutics for ALS. Since ALS is a multifacto-
rial disease and excitotoxicity is a contributing factor, combining 
LDN/OSU-0212320 with other agents that target different disease 
mechanisms may also provide greater effects (42).
In the epilepsy study, we pretreated mice with LDN/OSU-
0212320 prior to induction of seizures, which allowed us to 
evaluate the effects of LDN/OSU-0212320 at both the acute and 
chronic stages. The results showed that LDN/OSU-0212320 did 
not have significant effects on seizure severity at the acute stage, 
but significantly reduced the mortality rate, recurrent seizures, 
and neuronal death at the chronic stage. These results indicate 
that LDN/OSU-0212320 may have antiepileptogenesis function. 
During epileptogenesis, reactive astrocytes persistently upregulate 
mGluR5, which could enhance glutamate release (45). In addition, 
excessive glutamate could be released from astrocytes through vol-
ume-sensitive anion channels activated by cell swelling (46) and a 
Ca2+-dependent exocytosis triggered by inflammatory factors (47). 
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Antibodies. The following primary antibodies were used in this study: 
purified rabbit anti-EAAT2 pAb (1:2,000) (16); rabbit anti-EAAT3 pAb 
(1:300) (49); rabbit anti-EAAT4 pAb (1:500) (49); rabbit anti-EAAT1 pAb 
(1:1,000; Abcam); rabbit antiglutamine synthetase pAb (1:400; Santa Cruz 
Biotechnology Inc.); rabbit anti-GFAP pAb (1:1,000; Promega); mouse anti-
GAPDH mAb (1:3,000, Santa Cruz Biotechnology Inc.); rabbit anti-AKT 
mAb (1:3,000; Cell Signaling Technology); goat anti-actin pAb (1:3,000; 
Santa Cruz Biotechnology Inc.); mouse anti-actin mAb (1:5,000; Milli-
pore); mouse anti-MAP2 mAb (1:500; NeoMarker); rat anti-CD11b mAb 
(1:1,000; Chemicon International Inc.); mouse anti-VGLUT1 mAb (1:1,000; 
Millipore); and rabbit anti-NR2B pAb (1:1,000; Millipore).
Profiling and kinase studies. Profiling was performed by Caliper LifeSciences 
(now owned by PerkinElmer) in their General SEP I screening program to 
identify possible side effects from the compound. Seventy-one targets were 
tested in duplicate at 10 μM including 30 neurotransmitter-related recep-
tors, 2 steroids, 6 ion channels, including HERG binding, 1 second messen-
ger, 3 prostaglandins, 4 growth factors/hormones, 13 brain/gut peptides, 
5 enzymes, 7 cytochrome P450 isoenzymes (CYPs). For the detailed list, 
see Supplemental Table 1. Kinase profiling was performed by Nanosyn. 
Compound was tested at 1 and 10 μM for 230 kinases. The complete list of 
kinases is provided in Supplemental Table 3.
Statistics. The continuous quantitative data in this study were expressed as 
the mean ± SEM. χ2 tests were used to examine the distribution difference 
between vehicle- and compound-treated mice (54). The survival rates of 
SOD1(G93A) mice were compared between vehicle- and compound-treated 
groups by Kaplan-Meier survival analysis with a log-rank test. The repeated 
measures seizure data were analyzed using generalized linear mixed-effects 
models with a log link function. The correlation between hilar cell loss and 
chronic seizure frequency in SE mice was examined by the Spearman’s rank 
order correlation test. For multiple group comparisons, data were analyzed 
using 1-way ANOVA, with all pairwise multiple comparison procedures 
(Holm-Sidak method) when the data passed the normality and equal 
variance tests. Otherwise, data were analyzed using a Kruskal-Wallis test, 
with all pairwise multiple comparison procedures (Tukey’s test or Dunn’s 
method). For comparisons between two groups, a 2-tailed Student’s t test 
was performed when the normality assumptions were not violated. Other-
wise, a nonparametric Mann-Whitney rank sum test was performed. Values 
were considered significant at P < 0.05.
Study approval. All experiments were approved by the IACUC of the Ohio 
State University and were conducted within the terms of the NIH guide-
lines for the care and use of laboratory animals.
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WT mouse studies. WT adult C57Bl/6 mice received i.p. administration 
of LDN/OSU-0212320 at the indicated doses (Figure 3) in 500 μl of 1% 
DMSO/1% polyethylene glycol 400/0.2% Tween 80/10% hydroxypropyl- 
β-cyclodextrin/saline (or the indicated formulation) at the indicated time 
points (Figure 3). Tissue was then harvested either fresh or perfused with 
0.9% NaCl followed by 4% PFA in 0.1 M phosphate buffer (PB) for analy-
sis. Western blotting, [3H]glutamate uptake assays, cresyl violet staining, 
immunofluorescence staining, and real-time RT-PCR were performed as 
previously described (19, 29). Pharmacokinetic evaluation of LDN/OSU-
0212320 was performed using freshly isolated brain tissue. Briefly, after a 
single i.p. administration (3 mg/kg in 2% hydroxypropyl-β-cyclodextrin/
PBS) to male C57Bl/6 mice, plasma and brain concentrations were deter-
mined at 0.25, 0.5, 1, 2, and 8 hours by LC-MS/MS. The plasma half-life 
was estimated, and the average brain/plasma ratios were tested at all time 
points. These studies were performed by Absorption Systems.
SOD1(G93A) mouse studies. We followed the guidelines established by the 
ENMC Group (42). Mice received LDN/OSU-0212320 at the indicated 
doses (Figure 4) in 500 μl of 1% DMSO/1% polyethylene glycol 400/0.2% 
Tween 80/10% hydroxypropyl-β-cyclodextrin/saline starting at 84 days of 
age (6 times/week, at the same time each day) until death or until brain tis-
sues were harvested at 120 days of age for analysis. Western blotting, cresyl 
violet staining, and immunofluorescence staining were performed as pre-
viously described (51). Motor function was determined by measuring peak 
force using a digital grip dynamometer outfitted with a hind limb pull-
bar assembly (Columbus Instruments). Measurements started at 70 days 
of age (3 times/week, on the same day of each week and at the same time on 
each scheduled day) until the mouse lost all strength. Six repetitions were 
conducted, and the average was determined for each point. The examin-
ers were blinded to the treatment given to the mice. Food and water were 
placed on the cage floor when mice began to show motor deficits. Mice 
were euthanized when they were unable to roll over within 30 seconds after 
being placed on their sides. This time point was recorded as the time of 
death and as survival in days.
Epilepsy studies. Eight- to 10-week-old male FVB mice (22–32 g) received i.p. 
injections of LDN/OSU-0212320 (at the indicated dose in the formulation 
described above) 3 hours prior to the induction of seizures with pilocarpine 
(290 mg/kg i.p.; Sigma-Aldrich). To reduce peripheral cholinergic effects 
without interfering with the development of SE and chronic seizures, mice 
received scopolamine methyl nitrate (1.5 mg/kg; Sigma-Aldrich) 30 min-
utes prior to the pilocarpine injection. The control animals were injected 
with scopolamine followed by saline, instead of pilocarpine. Mice were then 
observed for 2 hours to record the acute seizure severity and the latency 
period. The Racine scale (52) was used to rate seizure severity as previously 
described (29). Mice that reached SE and maintained tonic limb extension 
for at least 60 minutes were kept and treated with compound daily for 
chronic seizure and pathological studies. The SE mice were fed with food 
soaked in a high-sucrose (10%) saline solution to help recovery in the first 
3 days after SE. Vehicle-treated SE mice and compound-treated SE litter-
mates were carefully matched based on body weight, seizure latency, seizure 
severity, and post-SE sickness. Therefore, the nature of the SE (i.e., seizure 
length and severity) in those mice was comparable. Chronic seizure activ-
ity was recorded by webcam (Logitech) and reviewed using Windows Live 
Movie Maker. Daylight periods (9 am–5 pm) were selected for observations, 
because the previous literature indicates a higher frequency of spontaneous 
recurrent seizures during the day (29, 53). Eight weeks after SE, brain tissues 
were harvested from SE mice for cresyl violet staining (29). Neurons that 
were stained with cresyl violet and that possessed a prominent nucleolus 
were counted under a light microscope at ×200 magnification. Six animals 
per group were analyzed. The correlation between hilar cell loss and chronic 
seizure frequency in SE mice was examined as previously described (29).
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